[ad_1]
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.
Other equities research analysts have also recently issued research reports about the stock. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $30.30 to $33.70 in a research note on Monday. JPMorgan Chase & Co. lifted their price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.81) to €51.00 ($54.26) and gave the stock an “underweight” rating in a report on Thursday, May 5th. Berenberg Bank reduced their price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($90.32) to €83.40 ($88.72) in a report on Thursday, March 17th. Finally, Truist Financial reduced their price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, six have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Hold” and an average price target of $52.51.
Shares of FMS opened at $24.94 on Friday. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $23.29 and a 52-week high of $42.13. The company has a quick ratio of 0.93, a current ratio of 1.26 and a debt-to-equity ratio of 0.51. The firm’s fifty day moving average is $28.74 and its two-hundred day moving average is $31.41. The stock has a market cap of $14.62 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 1.03 and a beta of 1.17.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last announced its earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.91% and a return on equity of 6.99%. The company had revenue of $5.10 billion for the quarter, compared to analysts’ expectations of $4.97 billion. As a group, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.93 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SRS Capital Advisors Inc. lifted its position in Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company’s stock valued at $52,000 after buying an additional 409 shares during the last quarter. Signaturefd LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% during the first quarter. Signaturefd LLC now owns 2,190 shares of the company’s stock worth $74,000 after purchasing an additional 458 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 53,824 shares of the company’s stock worth $1,747,000 after purchasing an additional 516 shares in the last quarter. Wetherby Asset Management Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 9.0% during the first quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company’s stock worth $229,000 after purchasing an additional 560 shares in the last quarter. Finally, Ellevest Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 96.6% during the fourth quarter. Ellevest Inc. now owns 1,148 shares of the company’s stock worth $37,000 after purchasing an additional 564 shares in the last quarter. 4.73% of the stock is currently owned by institutional investors.
About Fresenius Medical Care AG & Co. KGaA (Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
